Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
AirSculpt Technologies operates a network of body contouring centers offering proprietary minimally-invasive fat removal and body sculpting procedures under the AirSculpt brand. The company differentiates through its patented technology that requires no needles, scalpels, or general anesthesia, targeting affluent consumers willing to pay cash for elective cosmetic procedures. With ~30 centers across major U.S. metropolitan markets, the business faces severe operational stress evidenced by negative operating margins, declining revenue, and weak liquidity metrics.
Pure cash-pay elective procedure model with no insurance reimbursement dependency. Revenue generated per procedure with gross margins around 60% driven by proprietary technology and premium pricing. The company operates corporate-owned centers with centralized marketing and standardized protocols to maintain brand consistency. Pricing power derives from differentiated technology claims (faster recovery, less invasive) and targeting high-income demographics in major metros. However, current negative operating margins indicate center-level economics or corporate overhead structure are not sustainable at current scale.
Same-center sales growth and procedure volume trends - critical indicator of brand strength and demand sustainability
New center openings and ramp trajectory - expansion pace and time-to-profitability for new locations
Average revenue per procedure and pricing power - ability to maintain premium pricing amid competition
Path to profitability and cash burn rate - given negative margins and weak current ratio of 0.51, liquidity concerns dominate
Competitive threats from established medical spa chains and plastic surgery practices adopting similar technologies
Technology commoditization - competitors including established plastic surgeons and medical spa chains can adopt similar minimally-invasive techniques, eroding differentiation and pricing power
Regulatory risk - FDA scrutiny of marketing claims, state medical board oversight of physician-owned centers, potential changes to cosmetic procedure regulations
Reputational risk - adverse patient outcomes or negative social media sentiment can rapidly damage brand in consumer-facing elective medical market
Intense competition from established players like Sono Bello, CoolSculpting centers, traditional plastic surgery practices, and emerging med-spa chains with lower cost structures
Low barriers to entry for physicians to offer competing body contouring services using alternative technologies (laser lipolysis, cryolipolysis, radiofrequency)
Marketing spend arms race - customer acquisition costs may escalate as digital advertising becomes more competitive in aesthetic medicine vertical
Critical liquidity concerns - current ratio of 0.51 indicates insufficient short-term assets to cover liabilities, creating refinancing or capital raise pressure
Negative free cash flow and operating cash flow near zero create cash burn risk requiring external financing
Debt/equity ratio of 1.03 combined with unprofitability limits financial flexibility and increases refinancing risk if lenders tighten terms
Potential going-concern risk if unable to achieve profitability or secure additional capital given 70% stock decline suggests severe market confidence loss
high - Elective cosmetic procedures are highly discretionary luxury purchases that correlate strongly with consumer confidence, wealth effects, and disposable income. During economic downturns or recessions, demand contracts sharply as consumers defer non-essential medical spending. The $8,000-$15,000 average procedure price point targets affluent consumers whose spending patterns are sensitive to stock market performance and housing wealth.
Rising interest rates negatively impact the business through multiple channels: (1) higher cost of capital for expansion and working capital needs given the company's debt load (1.03 D/E ratio), (2) reduced consumer willingness to finance elective procedures through credit, (3) wealth effect compression as asset values decline, reducing discretionary spending capacity among target demographics. The company's negative free cash flow makes it particularly vulnerable to tightening financial conditions.
Moderate exposure. While procedures are cash-pay, many consumers likely use credit cards or medical financing (CareCredit, etc.) to fund treatments. Tightening consumer credit conditions or rising credit card rates could reduce conversion rates. The company's own creditworthiness affects its ability to finance expansion or refinance existing debt given current unprofitability.
Historically attracted growth investors betting on elective medical aesthetics market expansion and unit expansion model. Current 70% decline and distressed fundamentals now attract deep-value/special situations investors or those betting on turnaround execution. High volatility and small market cap ($100M) limit institutional ownership. Speculative profile given existential balance sheet risks.
high - Small-cap healthcare stock with binary outcomes around profitability achievement and capital structure sustainability. 56% decline in three months indicates extreme volatility. Illiquid trading and distressed fundamentals amplify price swings on any operational or financing news.
